Pharmaceutical Distribution Supply Chain

ICR 202407-0910-009

OMB: 0910-0806

Federal Form Document

Forms and Documents
Document
Name
Status
Form
Modified
Supporting Statement A
2025-05-02
ICR Details
0910-0806 202407-0910-009
Received in OIRA 202107-0910-010
HHS/FDA CDER
Pharmaceutical Distribution Supply Chain
Reinstatement with change of a previously approved collection   No
Regular 05/02/2025
  Requested Previously Approved
36 Months From Approved
74,375,565,700 0
2,550,820 0
0 0

This information collection implements the Drug Supply Chain Security Act. Manufacturers, repackagers, wholesale distributors, and dispensers must: (1) Notify FDA when they have determined that a product in their possession or control is illegitimate or if a manufacturer when they determine that a product has a high risk of illegitimacy; (2) terminate such notifications after consultation with FDA; (3) notify certain immediate trading partners about an illegitimate product or if a manufacturer about a product with a high risk of illegitimacy; and (4) notify immediate trading partners when such notifications are terminated.

US Code: 21 USC 360eee Name of Law: Drug Supply Chain Security Act
  
None

Not associated with rulemaking

  89 FR 72848 09/06/2024
90 FR 18675 05/01/2025
Yes

  Total Request Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 74,375,565,700 0 0 0 74,375,241,078 324,622
Annual Time Burden (Hours) 2,550,820 0 0 0 575,888 1,974,932
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No
Our estimated burden for the information collection reflects some significant increases; most notably burden we attribute to the task of documenting individual transaction information. We have also increased the number of respondents submitting WEE requests in response to public comment and as discussed at Q-12 of our SSA. We also note significant ongoing recordkeeping attributable to documenting activities along the supply chain that we regard as usual and customary in complying with the self-executing requirements of Drug Supply Chain Security Act set forth in sections 581 and 581 (Subchapter H – Pharmaceutical Distribution Supply Chain) of the FD&C Act.

$3,800
No
    Yes
    No
No
No
No
No
Domini Bean 301 796-5733 domini.bean@fda.hhs.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
05/02/2025


© 2025 OMB.report | Privacy Policy